Incyte Corporation (INCY)
$112.74+4.84%
Spriggl Score: Strong— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Cash-rich biotech with blockbuster earnings; 2028 patent expiry is the make-or-break test.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refract…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- $21.5B
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Incyte Corporation and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free